| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.078 | 0.008 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.008 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.093 | 0.008 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.008 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |